Amarin Lays Off 50% of Staff After Panel Rejects Vascepa
Specialty drugmaker Amarin Corp. is eliminating half of its employees after an FDA panels of experts voted not to recommend that the FDA expand the use of Amarin's omega-3 product, Vascepa.
The drugmaker had sought approval for use of the fish-oil drug with a cholesterol-lowering statin to reduce the risk of coronary disease. The FDA is yet to make its final decision, but Amarin is not hopeful.
Vascepa was approved in 2012 for a relatively narrow use in patients with unusually high triglyceride levels.
A majority of panelists said that while Vascepa significantly lowers fat levels, it is unclear whether that actually translates into fewer heart attacks.